Drug Approval | July 29, 2024
Briefs: Indoco Remedies and Alembic Pharmaceuticals
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"
Campaign launched to spread awareness regarding dengue prevention and control
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
The inspection was concluded with two 483 observations
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Subscribe To Our Newsletter & Stay Updated
